Abstract: The present invention is directed to a composition for intranasal administration comprising a CDNF polypeptide for use in the intranasal treatment of a central nervous system disease, such as Alzheimer's disease, Parkinson's disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, dementia with Lewy bodies, mild cognitive impairment, Huntington's disease, traumatic brain injury and stroke. The present invention is also directed to a composition for intranasal administration comprising a MANF polypeptide for use in the intranasal treatment of a central nervous system disease.
Type:
Application
Filed:
November 18, 2016
Publication date:
June 27, 2019
Applicant:
Herantis Pharma Plc
Inventors:
Henri Huttunen, Mikko Airavaara, Mart Saarma
Abstract: A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof.
Type:
Application
Filed:
October 17, 2014
Publication date:
May 23, 2019
Applicant:
HERANTIS PHARMA PLC.
Inventors:
Mart SAARMA, Juha LAUREN, Päivi LINDHOLM, Tonis TIMMUSK, Raimo TUOMINEN
Abstract: The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.
Type:
Grant
Filed:
September 9, 2014
Date of Patent:
March 14, 2017
Assignee:
HERANTIS PHARMA PLC.
Inventors:
Mart Saarma, Päivi Pulkkila, Merja Voutilainen, Johan Peränen, Raimo Tuominen, Mikko Airavaara, Veli-Matti Leppänen, Maria Lindahl, Jaan-Olle Andressoo
Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.
Type:
Grant
Filed:
February 26, 2008
Date of Patent:
September 8, 2015
Assignee:
HERANTIS PHARMA PLC.
Inventors:
Mart Saarma, Juha Lauren, Paivi Lindholm, Tonis Timmusk, Raimo Tuominen
Abstract: The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.
Type:
Application
Filed:
September 9, 2014
Publication date:
January 15, 2015
Applicant:
HERANTIS PHARMA, PLC.
Inventors:
Mart SAARMA, Päivi LINDHOLM, Merja VOUTILAINEN, Johan PERÄNEN, Raimo TUOMINEN, Mikko AIRAVAARA, Veli-Matti LEPPÄNEN, Maria LINDAHL, Jaan-Olle ANDRESSOO
Abstract: The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.
Type:
Grant
Filed:
April 30, 2009
Date of Patent:
October 7, 2014
Assignee:
Herantis Pharma PLC.
Inventors:
Mart Saarma, Päivi Lindholm, Merja Voutilainen, Johan Peränen, Raimo Tuominen, Mikko Airavaara, Veli-Matti Leppänen, Maria Lindahl, Jaan-Olle Andressoo